Abstract:The in situ prepared dilithio derivative of the known species 1-bromo-1'-(trimethylsilylamino)ferrocene (1) reacted with tBuPCl2 to form the first example of a [2]ferrocenophane ([2]FCP) bridged by nitrogen and phosphorus (2). Sulfurization of 2 followed by column chromatography on silica gel gave the expected [2]FCP with a tBu(S)PN(SiMe3) bridging moiety (3a) and its desilylated counterpart with a tBu(S)PNH bridging moiety (3b). The molecular structure of 3b was determined by single-crystal X-ray analysis (α … Show more
“…24 The reaction between 8a and 2 equivalents of (diacetoxyiodo)benzene (PIDA) in acetonitrile led to the isolation of ansa-ferrocene derivative 12a with 25% yield (Scheme 3). The unique structure of 12, quite different from previously reported nitrogen-containing ferrocenophanes, [32][33][34] encouraged us to optimize its synthesis (see SI for details).…”
Section: Scheme 1 Synthesis Of N-methylferrocenyl-ynamidesmentioning
The first synthesis of various N-metallocenyl ynamides has been developed and two strategies for the oxidative cyclization of N-ferrocenyl ynamide into ansa[3]-ferrocenylamide are also reported. The mechanism for the iodine(III)-triggered transfor-mation has been studied by means of DFT calculations, showing that it proceeds through a Concerted Iodination Deprotona-tion step.
“…24 The reaction between 8a and 2 equivalents of (diacetoxyiodo)benzene (PIDA) in acetonitrile led to the isolation of ansa-ferrocene derivative 12a with 25% yield (Scheme 3). The unique structure of 12, quite different from previously reported nitrogen-containing ferrocenophanes, [32][33][34] encouraged us to optimize its synthesis (see SI for details).…”
Section: Scheme 1 Synthesis Of N-methylferrocenyl-ynamidesmentioning
The first synthesis of various N-metallocenyl ynamides has been developed and two strategies for the oxidative cyclization of N-ferrocenyl ynamide into ansa[3]-ferrocenylamide are also reported. The mechanism for the iodine(III)-triggered transfor-mation has been studied by means of DFT calculations, showing that it proceeds through a Concerted Iodination Deprotona-tion step.
“…[13][14][15][16][17] The significant strain of the ferrocene unit in both the free form and metal complex species might facilitate ring-opening reactions to afford a rich chemistry that provides ring-expansion and ring-opened monomers and polymers. [18][19][20] Phosphorus-bridged [2]ferrocenophanes have been reported by several groups, including ours, [21][22][23][24][25][26] but their chemistry is still unexplored compared with that of the [1]ferrocenophanes. Allcock et al reported the first diphospha [2]ferrocenophane with two pentavalent phosphorus atoms in the ansa bridge.…”
The trivalent phosphorus-bridged [2]ferrocenophane complex 2 having NEt groups on the respective phosphorus centers was prepared, and its reactions as a diphosphine ligand were examined for iron and chromium carbonyl complexes. Both the phosphorus centers of 2 coordinated to Fe(CO) fragments to form (μ-2)-[Fe(CO)], while the bulkier Cr(CO) fragment formed only a monochromium complex [Cr(κ-2)(CO)]. Dissociation of CO from [Cr(κ-2)(CO)] changed the coordination mode of 2 from κ to κ to form [Cr(κ-2)(CO)] having a three-membered ring. A similar approach for the monoiron complex [Fe(κ-2)(CO)] did not afford a κ complex but instead an EtNPC(O)PNEt-bridged [3]ferrocenophane complex in which a CO fragment was inserted into the P-P bond of 2 and both the phosphorus centers coordinated to Fe(CO) as a chelate diphosphine. The reaction of this product with an Fe(CO) fragment gave μ-{Fe(CHPNEt)-κP:κP}-[Fe(CO)] (8), in which one terminal CO and the CO group between the two phosphorus atoms were lost to give an [FeFe]hydrogenase mimic having a bis(phosphido)ferrocene chelate as a bridging unit. The two NEt groups of the bridging unit were expected to work as protonation sites. The protonated NEt groups contributed to an improvement in the reduction potential of the complex to a less negative area, i.e., -2.3 V for the free 8 to -1.0 V for the diprotonated 8. The catalytic reduction of the proton, however, required a more negative potential of -2.0 V, which is almost comparable to that of the phosphido-bridged [FeFe]hydrogenase model complex having no protonation site.
“…Although there are several synthetic strategies reported for compound 1, [73][74][75][76][77] due to low obtainable yields, 73,[75][76][77] and apparently impure final product, 73,74,76,77 a newly reported pathway, which involves Staudinger-type reaction on 1,1′-azidobromoferrocene (Scheme 1A), 78 was used for this compound. Compound 1 was initially purified by column chromatography, followed by a flask-to-flask sublimation, which resulted in bright colored golden yellow crystals, which were found suitable for characterization by single crystal X-ray diffraction (Fig.…”
Section: Synthesis and Properties Of Ferrocene Bridged Pn-ligandsmentioning
confidence: 99%
“…Adapting a known procedure for reductive amination on aminoferrocenes, 77,79,80 compound 1 was further reacted with paraformaldehyde and NaCNBH 3 , in presence of glacial acetic acid to obtain N,N-dimethyl substituted 1,1′-azabromoferrocene 2 (Scheme 1B). When compound 2 was lithiated and in situ reacted with one equivalent of Ph 2 PCl or Mes 2 PCl, compound 3a and 3b were obtained in yields of 69% and 21%, respectively, calculated based on starting material 1 (Scheme 1B).…”
Two 1,1’-azaphospha substituted dppf-analogues Fc'(NMe2)(PPh2) (Ph = C6H5, Fc' = 1,1'-ferrocenediyl, 3a) and Fc'(NMe2)(PMes2) (Mes = 2,4,6-Me3C6H2, 3b) have been prepared, via reductive amination, followed by salt-metathesis (of 2), starting...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.